Molecular Pathways of Diabetic Kidney Disease Inferred from Proteomics

References

• Liu S, Gui Y, Wang MS, et al. Serum integrative omics reveals the landscape of human diabetic kidney disease. Mol Metab. 2021;54:101367. doi:10.1016/j.molmet.2021.101367
   PubMedGoogle Scholar
• Tofte N, Lindhardt M, Adamova K, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020;8:301–312. doi:10.1016/S2213-8587(20)30026-7
   PubMed Web of Science ®Google Scholar
• Gordin D, Shah H, Shinjo T, et al. Characterization of glycolytic enzymes and pyruvate kinase M2 in type 1 and 2 diabetic nephropathy. Diabetes Care. 2019;42:1263–1273. doi:10.2337/dc18-2585
   PubMed Web of Science ®Google Scholar
• Uyy E, Suica VI, Boteanu RM, et al. Diabetic nephropathy associates with deregulation of enzymes involved in kidney sulphur metabolism. J Cell Mol Med. 2020;24:12131–12140. doi:10.1111/jcmm.15855
   PubMed Web of Science ®Google Scholar
• Shah IM, Mackay SP, McKay GA. Therapeutic strategies in the treatment of diabetic nephropathy - a translational medicine approach. Curr Med Chem. 2009;16:997–1016. doi:10.2174/092986709787581897
   PubMed Web of Science ®Google Scholar
• Nicholas SB. Use of urinary proteomics in diagnosis and monitoring of diabetic kidney disease. Lancet Diabetes Endocrinol. 2020;8:261–262. doi:10.1016/S2213-8587(20)30067-X
   PubMed Web of Science ®Google Scholar
• Klein J, Ramirez-Torres A, Ericsson A, et al. Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney Int. 2016;90:1045–1055. doi:10.1016/j.kint.2016.06.023
   PubMed Web of Science ®Google Scholar
• Shao C, Wang Y, Gao Y. Applications of urinary proteomics in biomarker discovery. Sci China Life Sci. 2011;54:409–417. doi:10.1007/s11427-011-4162-1
   PubMed Web of Science ®Google Scholar
• Greco V, Piras C, Pieroni L, et al. Direct assessment of plasma/serum sample quality for proteomics biomarker investigation. Methods Mol Biol. 2017;1619:3–21.
   PubMedGoogle Scholar
• Overgaard AJ, Thingholm TE, Larsen MR, et al. Quantitative iTRAQ-based proteomic identification of candidate biomarkers for diabetic nephropathy in plasma of type 1 diabetic patients. Clin Proteomics. 2010;6:105–114. doi:10.1007/s12014-010-9053-0
   PubMedGoogle Scholar
• Cefalu WT, Bakris G, Blonde L, Boulton A, DAlessio D, Groot M. Standards of medical care in diabetes-2017: summary of Revisions. Diabetes Care. 2017;40:S4–S5. doi:10.2337/dc17-S003
   PubMed Web of Science ®Google Scholar
• Aluksanasuwan S, Plumworasawat S, Malaitad T, et al. High glucose induces phosphorylation and oxidation of mitochondrial proteins in renal tubular cells: a proteomics approach. Sci Rep. 2020;10:5843. doi:10.1038/s41598-020-62665-w
   PubMed Web of Science ®Google Scholar
• Lei L, Bai Y, Fan Y, et al. Comprehensive diagnostics of diabetic nephropathy by transcriptome RNA sequencing. Diabetes Metab Syndr Obes. 2022;15:3069–3080. doi:10.2147/DMSO.S371026
   PubMed Web of Science ®Google Scholar
• Mu X, Yang M, Ling P, et al. Acylcarnitines: can they be biomarkers of diabetic nephropathy? Diabetes Metab Syndr Obes. 2022;15:247–256. doi:10.2147/DMSO.S350233
   PubMed Web of Science ®Google Scholar
• Shen L, Zhao D, Chen Y, et al. Comparative proteomics analysis of serum proteins in gestational diabetes during early and middle stages of pregnancy. Proteomics Clin Appl. 2019;13:e1800060. doi:10.1002/prca.201800060
   PubMed Web of Science ®Google Scholar
• Moulder R, Bhosale SD, Goodlett DR, et al. Analysis of the plasma proteome using iTRAQ and TMT-based isobaric labeling. Mass Spectrom Rev. 2018;37(5):583–606. doi:10.1002/mas.21550
   PubMed Web of Science ®Google Scholar
• Bringans SD, Ito J, Stoll T, et al. Comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease. EuPA Open Proteom. 2017;14:1–10. doi:10.1016/j.euprot.2016.12.001
   PubMedGoogle Scholar
• Frantzi M, Latosinska A, Fluhe L, et al. Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol. 2015;12:317–330. doi:10.1038/nrurol.2015.100
   PubMed Web of Science ®Google Scholar
• Geyer PE, Holdt LM, Teupser D, et al. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol. 2017;13:942. doi:10.15252/msb.20156297
   PubMed Web of Science ®Google Scholar
• Siwy J, Zurbig P, Argiles A, et al. Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrol Dial Transplant. 2017;32:2079–2089. doi:10.1093/ndt/gfw337
   PubMed Web of Science ®Google Scholar
• Beasley-Green A. Urine proteomics in the era of mass spectrometry. Int Neurourol J. 2016;20:S70–75. doi:10.5213/inj.1612720.360
   PubMed Web of Science ®Google Scholar
• Li XQ, Chang DY, Chen M, et al. Complement activation in patients with diabetic nephropathy. Diabetes Metab. 2019;45:248–253. doi:10.1016/j.diabet.2018.04.001
   PubMed Web of Science ®Google Scholar
• Yang J, Liu D, Liu Z. Integration of metabolomics and proteomics in exploring the endothelial dysfunction mechanism induced by serum exosomes from diabetic retinopathy and diabetic nephropathy patients. Front Endocrinol. 2022;13:830466. doi:10.3389/fendo.2022.830466
   PubMed Web of Science ®Google Scholar
• Lindhardt M, Persson F, Zurbig P, et al. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial Transplant. 2017;32(11):1866–1873. doi:10.1093/ndt/gfw292
   PubMed Web of Science ®Google Scholar
• Khan NU, Lin J, Liu X, et al. Insights into predicting diabetic nephropathy using urinary biomarkers. Biochim Biophys Acta Proteins Proteom. 2020;1868:140475. doi:10.1016/j.bbapap.2020.140475
   PubMed Web of Science ®Google Scholar
• Limonte CP, Valo E, Drel V, et al. Urinary proteomics identifies cathepsin D as a biomarker of rapid eGFR decline in type 1 diabetes. Diabetes Care. 2022;45:1416–1427. doi:10.2337/dc21-2204
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Looker HC, Satake E, et al. Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes. Kidney Int. 2022;102:370–381. doi:10.1016/j.kint.2022.04.022
   PubMed Web of Science ®Google Scholar
• Ahn HS, Kim JH, Jeong H. et al. Differential urinary proteome analysis for predicting prognosis in type 2 diabetes patients with and without renal dysfunction. Int J Mol Sci. 2020:21. doi:10.3390/ijms22010021
   PubMed Web of Science ®Google Scholar
• Chen CJ, Liao WL, Chang CT, et al. Urine proteome analysis by C18 plate-matrix-assisted laser desorption/ionization time-of-flight mass spectrometry allows noninvasive differential diagnosis and prediction of diabetic nephropathy. PLoS One. 2018;13:e0200945. doi:10.1371/journal.pone.0200945
   PubMed Web of Science ®Google Scholar
• Patel DN, Kalia K. Characterization of low molecular weight urinary proteins at varying time intervals in type 2 diabetes mellitus and diabetic nephropathy patients. Diabetol Metab Syndr. 2019;11:39. doi:10.1186/s13098-019-0430-1
   PubMed Web of Science ®Google Scholar
• Chebotareva N, Vinogradov A, McDonnell V, et al. Urinary protein and peptide markers in chronic kidney disease. Int J Mol Sci. 2021;23(1):22. doi:10.3390/ijms23010022
   PubMedGoogle Scholar
• Guo Z, Liu X, Li M, et al. Differential urinary glycoproteome analysis of type 2 diabetic nephropathy using 2D-LC-MS/MS and iTRAQ quantification. J Transl Med. 2015;13:371. doi:10.1186/s12967-015-0712-9
   PubMed Web of Science ®Google Scholar
• Liao WL, Chang CT, Chen CC, et al. Urinary proteomics for the early diagnosis of diabetic nephropathy in Taiwanese patients. J Clin Med. 2018;7:483.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Pan CC, Chang HY, et al. SH3BGRL3 protein as a potential prognostic biomarker for urothelial carcinoma: a novel binding partner of epidermal growth factor receptor. Clin Cancer Res. 2015;21:5601–5611. doi:10.1158/1078-0432.CCR-14-3308
   PubMed Web of Science ®Google Scholar
• Araumi A, Osaki T, Ichikawa K, et al. Urinary and plasma proteomics to discover biomarkers for diagnosing between diabetic nephropathy and minimal change nephrotic syndrome or membranous nephropathy. Biochem Biophys Rep. 2021;27:101102. doi:10.1016/j.bbrep.2021.101102
   PubMedGoogle Scholar
• Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol. 2016;2016:4647685. doi:10.1155/2016/4647685
   PubMedGoogle Scholar
• Fan G, Gong T, Lin Y, et al. Urine proteomics identifies biomarkers for diabetic kidney disease at different stages. Clin Proteomics. 2021;18:32. doi:10.1186/s12014-021-09338-6
   PubMed Web of Science ®Google Scholar
• Al-Rubeaan K, Siddiqui K, Al-Ghonaim MA, et al. Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients. Sci Rep. 2017;7(1):2684. doi:10.1038/s41598-017-02421-9
   PubMedGoogle Scholar
• Panduru NM, Forsblom C, Saraheimo M, et al. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2013;36:2077–2083. doi:10.2337/dc12-1868
   PubMed Web of Science ®Google Scholar
• Garg V, Kumar M, Mahapatra HS, et al. Novel urinary biomarkers in pre-diabetic nephropathy. Clin Exp Nephrol. 2015;19(5):895–900. doi:10.1007/s10157-015-1085-3
   PubMed Web of Science ®Google Scholar
• Zurbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes. 2012;61:3304–3313. doi:10.2337/db12-0348
   PubMed Web of Science ®Google Scholar
• Canadas-Garre M, Anderson K, McGoldrick J, et al. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease. J Proteomics. 2019;193:93–122. doi:10.1016/j.jprot.2018.09.020
   PubMed Web of Science ®Google Scholar
• Lu H, Deng S, Zheng M, et al. iTRAQ plasma proteomics analysis for candidate biomarkers of type 2 incipient diabetic nephropathy. Clin Proteomics. 2019;16(1):33. doi:10.1186/s12014-019-9253-1
   PubMedGoogle Scholar
• Caseiro A, Ferreira R, Quintaneiro C, et al. Protease profiling of different biofluids in type 1 diabetes mellitus. Clin Biochem. 2012;45:1613–1619. doi:10.1016/j.clinbiochem.2012.08.027
   PubMed Web of Science ®Google Scholar
• Moresco RN, Sangoi MB, De Carvalho JA, et al. Diabetic nephropathy: traditional to proteomic markers. Clin Chim Acta. 2013;421:17–30. doi:10.1016/j.cca.2013.02.019
   PubMed Web of Science ®Google Scholar
• Bacci MR, Cavallari MR, de Rozier-Alves RM, et al. The impact of lipocalin-type-prostaglandin-D-synthase as a predictor of kidney disease in patients with type 2 diabetes. Drug Des Devel Ther. 2015;9:3179–3182. doi:10.2147/DDDT.S82100
   PubMed Web of Science ®Google Scholar
• Piktel E, Levental I, Durnas B, et al. Plasma gelsolin: indicator of inflammation and its potential as a diagnostic tool and therapeutic target. Int J Mol Sci. 2018;20(1):19. doi:10.3390/ijms20010019
   PubMedGoogle Scholar
• Cheng Y, Hu X, Liu C, et al. Gelsolin inhibits the inflammatory process induced by LPS. Cell Physiol Biochem. 2017;41:205–212. doi:10.1159/000456043
   PubMedGoogle Scholar
• Yang Y, Zhang S, Lu B, et al. Predicting diabetic nephropathy by serum proteomic profiling in patients with type 2 diabetes. Wien Klin Wochenschr. 2015;127:669–674. doi:10.1007/s00508-014-0679-1
   PubMed Web of Science ®Google Scholar
• Yamanouchi M, Skupien J, Niewczas MA, et al. Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int. 2017;92:258–266. doi:10.1016/j.kint.2017.02.010
   PubMed Web of Science ®Google Scholar
• Saulnier PJ, Gand E, Velho G, et al. Association of circulating biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) with renal function decline in patients with type 2 diabetes: a French prospective cohort. Diabetes Care. 2017;40:367–374. doi:10.2337/dc16-1571
   PubMed Web of Science ®Google Scholar
• Peters KE, Davis WA, Ito J, et al. Identification of novel circulating biomarkers predicting rapid decline in renal function in type 2 diabetes: the Fremantle diabetes study Phase II. Diabetes Care. 2017;40:1548–1555. doi:10.2337/dc17-0911
   PubMed Web of Science ®Google Scholar
• Peters KE, Xu J, Bringans SD, et al. PromarkerD predicts renal function decline in type 2 diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). J Clin Med. 2020;9(10):3212. doi:10.3390/jcm9103212
   PubMed Web of Science ®Google Scholar
• Beisswenger PJ, Howell SK, Russell GB, et al. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care. 2013;36(10):3234–3239. doi:10.2337/dc12-2689
   PubMed Web of Science ®Google Scholar
• El-Asrar MA, Adly AA, Ismail EA. Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control. Pediatr Diabetes. 2012;13:616–624. doi:10.1111/j.1399-5448.2012.00881.x
   PubMed Web of Science ®Google Scholar
• Niewczas MA, Pavkov ME, Skupien J, et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019;25:805–813. doi:10.1038/s41591-019-0415-5
   PubMed Web of Science ®Google Scholar
• Barutta F, Bellini S, Canepa S, et al. Novel biomarkers of diabetic kidney disease: current status and potential clinical application. Acta Diabetol. 2021;58(7):819–830. doi:10.1007/s00592-020-01656-9
   PubMed Web of Science ®Google Scholar
• Blutke A. Opening a treasure chest: glomerular proteome analyses of formalin-fixed paraffin-embedded kidney tissue in the investigation of diabetic nephropathy. Nephrol Dial Transplant. 2012;27(5):1695–1698. doi:10.1093/ndt/gfs082
   PubMed Web of Science ®Google Scholar
• Hoyer KJR, Dittrich S, Bartram MP, et al. Quantification of molecular heterogeneity in kidney tissue by targeted proteomics. J Proteomics. 2019;193:85–92. doi:10.1016/j.jprot.2018.03.001
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-D-glucosaminidase. Kidney Int. 2011;79:464–470. doi:10.1038/ki.2010.404
   PubMed Web of Science ®Google Scholar
• Fu WJ, Xiong SL, Fang YG, et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine. 2012;41:82–88. doi:10.1007/s12020-011-9509-7
   PubMed Web of Science ®Google Scholar
• Zubiri I, Posada-Ayala M, Benito-Martin A, et al. Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes. Transl Res. 2015;166:474–484 e474. doi:10.1016/j.trsl.2015.05.007
   PubMed Web of Science ®Google Scholar
• de la Cuesta F, Barderas MG, Calvo E, et al. Secretome analysis of atherosclerotic and non-atherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. J Proteomics. 2012;75:2960–2971. doi:10.1016/j.jprot.2011.12.005
   PubMed Web of Science ®Google Scholar
• Mi H, Poudel S, Muruganujan A, et al. PANTHER version 10: expanded protein families and functions, and analysis tools. Nucleic Acids Res. 2016;44(D1):D336–D342. doi:10.1093/nar/gkv1194
   PubMed Web of Science ®Google Scholar
• Rossi C, Marzano V, Consalvo A, et al. Proteomic and metabolomic characterization of streptozotocin-induced diabetic nephropathy in TIMP3-deficient mice. Acta Diabetol. 2018;55:121–129. doi:10.1007/s00592-017-1074-y
   PubMed Web of Science ®Google Scholar
• Satirapoj B, Tassanasorn S, Charoenpitakchai M, et al. Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus. PLoS One. 2015;10:e0124055. doi:10.1371/journal.pone.0124055
   PubMed Web of Science ®Google Scholar
• Jung CY, Yoo TH. Pathophysiologic mechanisms and potential biomarkers in diabetic kidney disease. Diabetes Metab J. 2022;46:181–197. doi:10.4093/dmj.2021.0329
   PubMed Web of Science ®Google Scholar
• Nakatani S, Wei M, Ishimura E, et al. Proteome analysis of laser microdissected glomeruli from formalin-fixed paraffin-embedded kidneys of autopsies of diabetic patients: nephronectin is associated with the development of diabetic glomerulosclerosis. Nephrol Dial Transplant. 2012;27:1889–1897. doi:10.1093/ndt/gfr682
   PubMed Web of Science ®Google Scholar
• Fugmann T, Borgia B, Revesz C, et al. Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy. Kidney Int. 2011;80:272–281. doi:10.1038/ki.2011.116
   PubMed Web of Science ®Google Scholar
• Winiarczyk D, Winiarczyk M, Michalak K, et al. Urinary proteome differences in canine diabetes with and without the presence of microalbuminuria. Animals. 2022;12(6):748. doi:10.3390/ani12060748
   Web of Science ®Google Scholar
• Jin J, Gong J, Zhao L, et al. iTRAQ-based comparative proteomics analysis reveals specific urinary biomarkers for various kidney diseases. Biomark Med. 2020;14(10):839–854. doi:10.2217/bmm-2019-0556
   PubMed Web of Science ®Google Scholar
• Bellei E, Monari E, Bergamini S, et al. Urinary proteomics in biomarker discovery of kidney-related disorders: diabetic nephropathy and drug-induced nephrotoxicity in chronic headache. EJIFCC. 2018;29:290–297.
   PubMedGoogle Scholar
• Guillen-Gomez E, Bardaji-de-quixano B, Ferrer S, et al. Urinary proteome analysis identified neprilysin and VCAM as proteins involved in diabetic nephropathy. J Diabetes Res. 2018;2018:6165303. doi:10.1155/2018/6165303
   PubMed Web of Science ®Google Scholar
• El-Beblawy NM, Andrawes NG, Ismail EA, et al. Serum and urinary orosomucoid in young patients with type 1 diabetes: a link between inflammation, microvascular complications, and subclinical atherosclerosis. Clin Appl Thromb Hemost. 2016;22:718–726. doi:10.1177/1076029616637185
   PubMed Web of Science ®Google Scholar
• Overgaard AJ, Hansen HG, Lajer M, et al. Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Sci. 2010;8:4. doi:10.1186/1477-5956-8-4
   PubMed Web of Science ®Google Scholar
• Malagrino PA, Venturini G, Yogi PS, et al. Proteome analysis of acute kidney injury - Discovery of new predominantly renal candidates for biomarker of kidney disease. J Proteomics. 2017;151:66–73. doi:10.1016/j.jprot.2016.07.019
   PubMed Web of Science ®Google Scholar
• Chun N, Wyatt CM, He JC. Identification of a protective proteomic signature and a potential therapeutic target in diabetic nephropathy. Kidney Int. 2017;92:780–781. doi:10.1016/j.kint.2017.08.002
   PubMed Web of Science ®Google Scholar
• Fallon JK, Smith PC, Xia CQ, et al. Quantification of four efflux drug transporters in liver and kidney across species using targeted quantitative proteomics by isotope dilution NanoLC-MS/MS. Pharm Res. 2016;33:2280–2288. doi:10.1007/s11095-016-1966-5
   PubMed Web of Science ®Google Scholar
• Konvalinka A, Zhou J, Dimitromanolakis A, et al. Determination of an angiotensin II-regulated proteome in primary human kidney cells by stable isotope labeling of amino acids in cell culture (SILAC). J Biol Chem. 2013;288:24834–24847. doi:10.1074/jbc.M113.485326
   PubMed Web of Science ®Google Scholar